Psilocybin as a Novel Therapy for Residual Anhedonia
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
NYU Langone Health
90 participants
Sep 1, 2026
INTERVENTIONAL
Conditions
Summary
This study is for adults with major depressive disorder (depression) who are currently taking an SSRI or SNRI antidepressant but continue to experience anhedonia (reduced interest or pleasure) and emotional blunting. The study will test whether a single 25 mg dose of psilocybin, compared with placebo, can improve these symptoms and improve the function of brain circuits involved in reward and motivation. Researchers will measure changes using brain imaging (fMRI) and clinical questionnaires, including the Dimensional Anhedonia Rating Scale (DARS).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
One-time dose of psilocybin 25 mg, oral, in capsule form.
One-time dose of placebo (25 mg of inert filler), oral, in capsule form.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07607938